Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.50+0.04 (+1.16%)
Close on Nov 18, 2026Market cap $226.67MP/E –Yield –
Immuneering net income
Net income is the profit left for shareholders after every expense, interest and tax.
Immuneering's net income for the twelve months ending Sep 30, 2026 was -$66.50M. For fiscal 2025 it was -$56.02M. The highest annual figure on record is -$17.04M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$56.02M | – |
| FY2024 | Dec 31, 2024 | -$61.04M | – |
| FY2023 | Dec 31, 2023 | -$53.47M | – |
| FY2022 | Dec 31, 2022 | -$50.51M | – |
| FY2021 | Dec 31, 2021 | -$33.54M | – |
| FY2020 | Dec 31, 2020 | -$17.04M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.19M | – |
| Q2 FY2026 | Jun 30, 2026 | -$17.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$13.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.58M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.96M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.31M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.60M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.90M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.78M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.20M | – |
See a number that looks wrong?